---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038002"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:59:18.903306+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023

## Summary
- Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.
- Cash, cash equivalents, and marketable securities $325.9M as of June 30, 2023, expected to fund operations into 2025.
- Enrolling patients in ARDENT Phase 1 trial for SC291 (CD19 CAR T) in B-cell malignancies; initial clinical data expected in H2 2023.
- Plan to file IND for SC262 and SG299 in hematologic cancers and SC451 (islet cell) in type 1 diabetes in 2024.
- Appointed Doug Williams as President of R&D and Gary Meininger as CMO.

## SEC filing metadata
- accession: 0000950170-23-038002
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/0000950170-23-038002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/sana-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038002
- JSON: https://secwatch.observer/filing/0000950170-23-038002.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038002.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the quarter and year ended June 30, 2023.
  - Period: the quarter and year ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017023038002/0000950170-23-038002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.